Sandoz Receives Canadian Approval for Generic Ozempic and Biosimilar Licensing Deal
Sandoz has received approval in Canada to market a generic version of Novo Nordisk’s GLP-1 therapy, Ozempic. This marks an important step as the drug is off-patent, allowing Sandoz to enter this competitive therapeutic space with potentially lower-cost alternatives. In addition to the Ozempic approval, Sandoz has entered into a licensing agreement with mAbxience for a biosimilar targeting Roche’s Hemlibra. This partnership could expand Sandoz's portfolio in biologics and biosimilars, leveraging mAbxience’s expertise under Fresenius ownership. The approvals are significant as they position Sandoz to compete more directly with major pharmaceutical players like Novo Nordisk and Roche while offering cost-effective alternatives for patients.
Topics: biosimilars GLP-1 therapy Hemlibra biosimilar licensing agreements